OS Therapies OSTX 深 沪
等待开盘 10-07 09:30:00 美东时间
1.49
-0.110
-6.87%
华盛通- 最 高1.7401
- 今 开1.71
- 成交量 598.47万股
- 最 低 1.47
- 昨 收 1.60
- 总市值 6.92万
- 52周最高 2.25
- 市盈率 静 --
- 换手率 12878.39%
- 52周最低 1.15
- 委 比 83.24%
- 总股本 4.65万
- 历史最高 7.00
- 量 比 14.93
- 振 幅 16.88%
- 历史最低 1.12
- 每 手 1
- 风险率 0.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment
OS Therapies Inc. (NYSE:OSTX) announced a statistically significant three-year overall survival benefit for patients treated with OST-HER2 in its Phase 2b trial. The study evaluated the prevention or delay of recurrence in patients with fully resected, pulmonary metastatic osteosarcoma. Osteosarcoma...
今天 01:19
OS Therapies Appoints Frank Knuettel II As CFO
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced the appointment of Kerry Clem as Chief Commercial Officer (CCO) and Frank Knuettel II as Chief Financial Officer (CFO).
10-01 20:34
OS Therapies Achieves Full Alignment With UK MHRA On Its Pending Conditional Marketing Authorization Application
MHRA agreed that the use of comparable historical control data – derived from a systematic evaluation of all suitable available peer-reviewed literature by independent biostatistics advisors presented in its most recent Scientific Advice Meeting (SAM) - was appropriate in the orphan indication Preve...
09-15 19:50
OS Therapies Announces Statistically Significant Benefit For OST-HER2-Treated Patients In An Interim 3-Year Overall Survival Data Analysis
Overall survival data when compared with a combined published historical control arm being used for regulatory interactions. The analysis is from the Company's Phase 2b trial for the prevention or delay of recurrence in patients with fully resected, pulmonary metastatic osteosarcoma (the "Metastatic...
09-08 18:09
OS Therapies Enters Open Market Sale Agreement With Jefferies; May Offer Common Stock Up To $75M Through Jefferies
OS Therapies Enters Open Market Sale Agreement With Jefferies; May Offer Common Stock Up To $75M Through Jefferies
08-22 04:46
OS Therapies Announces Convertible Note Financing and Warrants
OS Therapies Incorporated ( ($OSTX) ) has provided an update. On August 10, 202...
08-13 05:19
OS Therapies Settles Leonite Debt, Issues Bridge Financing
An update from OS Therapies Incorporated ( ($OSTX) ) is now available. On June ...
08-07 04:46
OS Therapies Ends At-The-Market Equity Sales Program
OS Therapies Incorporated ( ($OSTX) ) just unveiled an announcement. On July 23...
07-30 05:29
OS Therapies Terminates At Market Issuance Sales Agreement On July 23; Co. Announces Termination Of Sales Agreement Effective July 28
OS Therapies Terminates At Market Issuance Sales Agreement On July 23; Co. Announces Termination Of Sales Agreement Effective July 28
07-30 05:15
美股大行评级 | 潜在涨幅246.92%！HC Wainwright & Co.上调Rockwell Medical(RMTI)目标价至20美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Rockwell Medical"买入"评级，目标价从2美元升至20美元；Canaccord Genuity：维持创力"买入"评级，目标价从10.5美元升至11美元
07-10 17:36
